Assistant Controller

Mavericks Wanted

When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on

In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.

Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.

What You’ll Do

The Senior Director, Assistant Controller is a key member of the accounting leadership team, reporting directly to the VP, Corporate Controller and serving as the VP Corporate Controller’s deputy for consolidation, close governance and accounting operations. This role is both technical and operational in nature, overseeing areas such as, but not limited to, consolidation and noncontrolling interest accounting, affiliate reporting and stand-alone audits, accounting systems and business processes, accounts payable, special projects, and BridgeBio’s overseas outsourced accounting team. The role also leads the accounting team’s desktop procedures program, process streamlining, and AI and automation agenda across all accounting functions. The role works closely with, but is separate from, the Technical Accounting and SEC Reporting function, which owns technical conclusions on complex and non-standard transactions as well as external financial reporting.

The role also partners with, rather than owns, revenue and cost accounting, R&D and sales & marketing accounting, payroll and stock compensation, tax, treasury, and the SOX program, which remain with their respective leaders.

The ideal candidate is a hands-on controllership leader with a strong technical foundation and a process-improvement mindset who is comfortable partnering with stakeholders across the organization. This individual thrives in a fast-paced, evolving commercial biotech environment, is agile in adapting to shifting priorities, and is equally effective managing day-to-day operations and leading process improvement, automation, and change management initiatives.

Responsibilities

Controllership: Close, Consolidation & Reporting Support

Close Governance & Financial Reporting

• Partner with the Senior Director, Accounting (G&A, general ledger, and intercompany accounting) and other functional accounting leaders to ensure timely, accurate inputs to the close
• Review the consolidated close package, schedules, disclosures, and supporting documentation, and provide them to the SEC Reporting team for SEC filings (e.g., Forms 10-Q and 10-K) and other regulatory reporting requirements
• Prepare and/or review affiliate financial statements and related reports
• Manage external auditor relationships for BridgeBio and its affiliates, including coordination of audit and quarterly review timelines and prepared-by-client (PBC) requests

Noncontrolling Interests & Consolidation

• Own the accounting for noncontrolling interests and variable interest entities, including allocation of income/loss and equity roll-forwards
• Own the consolidation process and related controls, including review of intercompany eliminations, foreign currency translation, and equity method investments, as applicable
• Ensure consolidation and noncontrolling interest accounting complies with U.S. GAAP and is properly documented and supportable for audit, in consultation with Technical Accounting and SEC Reporting

Partnership with Technical Accounting and SEC Reporting